An interview in French with our CEO on Europe 1
Discover how Deeptech is transforming medicine. In this episode, Wahid Awad shares his vision of life-saving innovations.
- Deeptech transforming medicine, in French
- Vision of life-saving innovations in oncology
- Featured on Europe 1 radio
Interview with our CEO: The Future of Precision Oncology
Dr. Wahid Awad and Dr. Muhammad Younis discuss the future of cancer care, featured by the London Biotechnology Show.
- Limitations of standard cancer treatments
- Transformative power of AI, multiomics and spatial biology
- How Rosetta Omics builds predictive models that enhance outcomes and lower costs
- Real-world challenges of clinical adoption
Interview with our CEO, Sejelas
An exclusive conversation with Dr. Wahid Awad on his journey, vision and mission to transform cancer care.
- Personal journey from academia to entrepreneurship
- How losing his father to cancer inspired Rosetta Omics
- Predictive models to improve outcomes and reduce healthcare costs
- Closing words: "You only fail when you give up."
Interview of our CEO featured in ActusPaysBas
Featured (in French) in ActusPaysBas, Dr. Wahid Awad reflects on his 16-year relationship with the Netherlands and stronger Franco-Dutch collaboration.
- 16-year relationship with the Netherlands since 2008
- Importance of Franco-Dutch public/private collaboration
- Netherlands as a leader in life sciences and translational research
- Strengthening international ties to fight cancer
Interview with our CEO: Unlocking Cancer's Secrets with AI & Multiomics
On the Life Science Success podcast, Dr. Wahid Awad discusses how AI and spatial multiomics are reshaping cancer care.
- How AI and spatial multiomics reshape cancer care
- Personal journey from academia to entrepreneurship
- Challenges of bringing precision oncology to patients worldwide
- Why international collaboration is key to scaling innovation
Webinar Replay: Precision Oncology in Action
Dr. Wahid Awad spoke at a webinar dedicated to advancing cancer diagnostics and drug development.
- Seamless integration into standard clinical biopsy procedure
- Actionable insights for oncologists in treatment decisions
- Identification of biomarkers of clinical interest
- Support for new drug-target discovery and innovation
